Taysha Gene Therapies (NASDAQ:TSHA) Insider Sukumar Nagendran Sells 200,000 Shares of Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction on Friday, July 10th. The stock was sold at an average price of $6.24, for a total value of $1,248,000.00. Following the completion of the transaction, the insider directly owned 936,410 shares of the company’s stock, valued at approximately $5,843,198.40. The trade was a 17.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Taysha Gene Therapies Price Performance

Shares of TSHA stock traded down $0.23 during midday trading on Friday, reaching $6.34. 2,850,052 shares of the company were exchanged, compared to its average volume of 3,779,284. Taysha Gene Therapies, Inc. has a 12 month low of $2.34 and a 12 month high of $7.30. The company has a debt-to-equity ratio of 0.23, a quick ratio of 14.04 and a current ratio of 14.04. The company has a market cap of $1.82 billion, a P/E ratio of -16.68 and a beta of 1.17. The company’s 50 day moving average price is $6.15 and its two-hundred day moving average price is $5.36.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). On average, sell-side analysts expect that Taysha Gene Therapies, Inc. will post -0.49 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Marex Group plc acquired a new stake in shares of Taysha Gene Therapies during the 2nd quarter valued at $29,000. E Fund Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies during the 2nd quarter valued at about $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in Taysha Gene Therapies in the third quarter worth approximately $40,000. Tower Research Capital LLC TRC raised its position in Taysha Gene Therapies by 156.5% during the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock valued at $41,000 after acquiring an additional 10,742 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Taysha Gene Therapies by 143.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after acquiring an additional 4,607 shares during the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on TSHA. Citizens Jmp reiterated a “market outperform” rating and issued a $11.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, July 2nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, June 30th. Chardan Capital reissued a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Robert W. Baird increased their target price on Taysha Gene Therapies from $12.00 to $15.00 and gave the company an “outperform” rating in a report on Tuesday, June 30th. Finally, Wall Street Zen cut Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Taysha Gene Therapies presently has a consensus rating of “Buy” and an average price target of $12.62.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.